Skip to search formSkip to main contentSkip to account menu

Wy 41195

Known as: Wy 41,195, Wy-41,195, Wy-41195 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
1986
Review
1986
The development of Wy-41,195, an orally effective antiallergic drug in animal models
Introduction Disodium cromoglycate (DSCG) administered by aerosol is well established as a prophylactic treatment for asthma… 
1985
1985
The topical effects of Wy-41,195 [2-cyano-3-(methylamino)phenylamino] oxoacetic acid, sodium salt and disodium cromoglycate in the rat passive eyelid anaphylaxis.
Wy-41,195 demonstrated significant inhibitory effects (54-60%) when administered topically at 0.25-2% concentrations in a rat… 
1984
1984
The effects of antiallergic and bronchodilator drugs on platelet-activating factor (PAF-acether) induced bronchospasm and platelet aggregation
Platelet activating factor (PAF-acether) is a potential mediator of asthma and inflammation. Recently, the suggestion was made… 
1984
1984
Modulation of sulfur dioxide-induced airways hyperresponsiveness in the conscious dog.
Brief exposure of conscious dogs to 30 ppm SO2 directly into the lungs resulted in a transient bronchoconstriction followed by a… 
1982
1982
The pharmacologic profile of wy-41,195, a new orally effective antiallergic agent.
[2-Cyano-3-(methylamino)phenylamino]oxoacetic acid, sodium salt (Wy-41,195) was found to be a potent oral inhibitor (viz., ED50… 
1982
1982
WY-41,195